Codexis, Inc. (CDXS) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Codexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing high-performance enzymes and proteins using its proprietary CodeEvolver directed evolution platform. Key business segments include the ECO Synthesis manufacturing platform for RNAi therapeutics and small molecule pharma biocatalysis. The company operates as a single reportable segment.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in thousands) |
|---|---|
| Total Revenues | $30,163 |
| Net Loss | $(20,709) |
| Net Loss Per Share (Basic & Diluted) | $(0.23) |
| Product Gross Margin | 73% |
| Cash, Cash Equivalents, and Restricted Cash | $29,206 |
| Short-term Investments | $27,746 |
| Total Debt (Current + Long-term) | $40,876 |
| Working Capital | $48,405 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 32% year-over-year (YoY) to $30.2 million for the six months ended June 30, 2026, compared to $22.9 million in 2025. This was driven primarily by a 52% increase in product revenue ($20.4 million vs. $13.4 million), offset by a slight 3% increase in R&D revenue.
- Improved Profitability: Net loss decreased significantly by 39% to $20.7 million from $34.0 million in the prior year period. Operating loss improved by 42% to $19.3 million.
- Expense Reduction: Total operating expenses decreased 12% YoY to $49.4 million. R&D expenses dropped 13% and SG&A expenses dropped 16%, largely due to lower headcount and reduced stock-based compensation.
- Liquidity Position: Cash and cash equivalents decreased from $50.8 million at year-end 2025 to $27.2 million at June 30, 2026, reflecting a net cash outflow from operating activities of $22.8 million.
Outlook, Risks, and Unusual Items
- Subsequent Event (Capital Raise): In July 2026, the company completed an underwritten public offering of approximately 18 million shares at $1.50 per share, raising net proceeds of approximately $23.1 million. This strengthens the liquidity position post-reporting period.
- Debt Obligations: The company has a $40.0 million term loan with Innovatus (Innovatus Loan) maturing in February 2029. The loan carries a floating interest rate and includes payment-in-kind (PIK) interest features. As of June 30, 2026, the company was in compliance with all covenants.
- Strategic Expansion: Management is advancing the ECO Synthesis platform, including a lease for a new GMP manufacturing facility in Hayward, California, with construction expected to commence in the second half of 2026.
- Risk Factors: Key risks include dependence on a limited number of customers (top customers accounted for 60% of revenue in the first half of 2026), reliance on third-party contract manufacturers, the unproven nature of enzymatic nucleic acid synthesis at scale, and the need for additional capital to fund operations and facility buildouts.
Investor Verification Checklist
- Cash Runway: Verify the impact of the July 2026 capital raise on the company's ability to fund operations for the next 12-24 months, given the historical burn rate.
- Customer Concentration: Assess the risk associated with the top customers contributing 60% of revenue and the potential impact of contract non-renewals.
- Debt Covenants: Review the specific financial covenants in the Innovatus Loan agreement to ensure continued compliance as the company scales.
- ECO Synthesis Adoption: Monitor progress on the new GMP facility and the status of partnerships with CDMOs for commercial-scale manufacturing.
- Revenue Quality: Analyze the sustainability of product revenue growth versus the volatility of milestone-based R&D revenue.